Salacyn
Loading...Salacyn Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
Prolonged and repeated daily use over large areas, especially in children and those patients with significant renal or hepatic impariment could result in salicylism. Concomitant use of other drugs which may contribute to elevated serum salucylate levels should be avoided where the potential for toxicity is present. In children under 12 years of age and those patients with renal of hepatic impairment to the area to be treated should be limited and the patient monitored closely for signs of salicylate toxicity; nausea, vomiting, dizziness, loss of hearing, tinnitus, lethargy, hyperpnea, diarrhea, and psychic disturbances. In the event of salicylic acid toxicity, the use of SALACYN™ 6% should be discontinued. Fluids should be administered to promote urinary execration. Treatment with sodium bicarbonate (oral or intravenous) should be instituted as appropriate. Patients should be cautioned against the use of oral aspirin and other salicylate containing medications, such as sports injury creams, to avoid additional excessive exposure to salicylic acid. Where needed, aspirin should be replaced by an alternative non-steroidal anti-inflammatory agent that is not salicylate based. Patients should be advised not to apply occlusive dressings, clothing or other occlusive topical products such as petrolatum-based ointments to prevent excessive systemic exposure to salicylic acid. Excessive application of the product other than is needed to cover the affected area will not result in a more rapid therapeutic benefit.
Due to the potential risk of developing Reye's syndrome, salicylate products should not be used in children and teenagers with varicella or influenza, unless directed by a physician.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
SALACYN™ 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris and psoriasis (including body, scalp, palms and soles).
SALACYN™ 6% is a topical aid in the removal of excessive keratin on dorsal and plantar hyperkeratotic lesions. Topical preparations of 6% salicylic acid have been reported to be useful adjunctive therapy for verrucae plantares.
History
There is currently no drug history available for this drug.
Other Information
SALACYN™ 6% CREAM contains 6% Salicyclic Acid USP incorporated into a specially formulated oil and water emulsion vehicle consisting of Ammonium Lactate, Cetearyl Alcohol and PEG-3 Distearoylamidoethylmonium Methosulfate and Polysorbate 60, Cetearyl Alcohol, Cetyl Alcohol, Dimethicone 350, Disodium EDTA, Glycerin, Glyceryl Stearate SE, Methylparaben, Mineral Oil, PEG-100 Stearate, Phenoxyethanol, Propylparaben, Purified Water and Trolamine.
SALACYN™ 6% LOTION contains 6% w/w Salicylic Acid USP incorporated into a specially formulated oil and water emulsion vehicle consisting of of Ammonium Lactate, Cetearyl Alcohol and PEG-3 Distearoylamidoethylmonium Methosulfate and Polysorbate 60, Cetyl Alcohol, Dimethicone 350, Disodium EDTA, Glycerin, Glyceryl Stearate SE, Methylparben, Mineral Oil, PEG-100 Stearate, Propylparaben, Purified Water and Trolamine.
Salicylic Acid is the 2-hydroxy derivative of benzoic acid having the following structure:
Sources
Salacyn Manufacturers
-
Stratus Pharamceuticals, Inc
![Salacyn (Salicylic Acid) Cream Salacyn (Salicylic Acid) Lotion [Stratus Pharamceuticals, Inc]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Salacyn | Stratus Pharamceuticals, Inc
The preferable method of use is to apply SALACYN™ 6% thoroughly to the affected area and to cover the treated area at night after washing and before retiring. Preferably, the skin should be hydrated for at least five minutes prior to application. The medication is washed off in the morning and if excessive drying and/or irritation is observed, a bland cream or lotion may be applied. Once clearing is apparent, the occasional use of SALACYN™ 6% will usually maintain the remission. In those areas where occulsion is difficult or impossible, application may be made more frequently; hydration by wet packs or baths prior to application apparently enhances the effect. (SEE WARNINGS). Unless hands are being treated, hands should be rinsed thoroughly after application. Excessive repeated application of SALACYN™ 6% will not necessarily increase its therapeutic benefit, but could result in increased local intolerance and systemic adverse effects such as salicylism.
Login To Your Free Account